FineTest ELISA kit contributes to the research on antidepressants for depression. The immunoassay is designed to measure liraglutide level in supernatant.
Article Title: Microbiota-driven gut-brain signaling underlies antidepressant effects of a GLP-1 analog
Journal Title: Cell Host & Microbe
DOI: 10.1016/j.chom.2026.05.003
IF: 23.2
PMID: 42269582
Abstract: Despite widespread clinical use of glucagon-like peptide-1 receptor (GLP-1R) agonists for metabolic disease, their neuropsychiatric effects remain poorly understood and controversial. Here, we demonstrate that liraglutide alleviates depression through a gut-brain pathway that operates independently of GLP-1R. Using both pharmacological and genetic approaches, we demonstrated that liraglutide retained antidepressant efficacy in GLP-1R antagonist-Exn9-treated mice or in Glp1r-/- mice, whereas gut microbiota depletion abolished its effects. Multi-omics analyses revealed that liraglutide increased the abundance of Lactobacillus delbrueckii, which in turn restored the levels of the endocannabinoid 2-arachidonoylglycerol (2-AG). The elevation of 2-AG mediated the antidepressant effects by normalizing excessive neuronal activity in emotional processing brain regions. Importantly, fecal microbiota transplantation from liraglutide-treated mice or Lactobacillus delbrueckii colonization replicated the antidepressant effects. These findings uncover a non-canonical mechanism of action for GLP-1 analogs, highlighting a specific microbiota-endocannabinoid metabolic pathway as a potential therapeutic target for depression.
Keywords: 2-AG, GLP-1 analog, Lactobacillus delbrwueckii, depression, neuronal hyperactivation, Antidepressants
Immunoassay
| FineTest Product | Sample | Species | Detection Target |
| LRT (Liraglutide) ELISA Kit(EU2618) | supernatant | mice | Liraglutide |
Validated Image

Figure Source: Cell Host Microbe. 2026 Jun 10;34(6):1000-1017.e5. doi: 10.1016/j.chom.2026.05.003.